Lightnews — Scholar-powered news

Reposted by Erin Michos, MD

allisonghaysmd.bsky.social @allisonghaysmd.bsky.social · Sep 7

Great @hopkinsheart.bsky.social representation @ase360.bsky.social @mmukherjeemd.bsky.social @erinmichos.bsky.social

4 6

Reposted by Erin Michos, MD

allisonghaysmd.bsky.social @allisonghaysmd.bsky.social · Sep 7

Excellent session on women’s heart health across the lifespan and role of Echo at #ASE2025
Featuring @erinmichos.bsky.social (women’s health leader @HopkinsHeart) @anabarac (pioneer in cardio-oncology), masterfully chaired by @sharonmulvagh expert in Echo and women’s CV health

1 2 3

Erin Michos, MD @erinmichos.bsky.social · Sep 2

CAC score 14 is the 84th %tile for 55yo woman! Calcified plaque is late stage plaque, she likely has non calcified plaque as well (not captured by CAC) amenable to regression if treated now. Given young age, has lot of life yrs at risk. Would treat with statin, aim for LDLC<70 & apoB<70. Check Lp(a)

2

Reposted by Erin Michos, MD

American Journal of Preventive Cardiology @ajpcardio.bsky.social · Aug 11

New study alert: Women with established coronary artery disease are less likely than men to receive guideline-based statin therapy—and face higher rates of recurrent cardiovascular events. Ensuring equal treatment equity could save more lives. Read more: www.sciencedirect.com/science/arti...

1 6 7

Reposted by Erin Michos, MD

Endocrinology Advisor @endocrinologyadv.bsky.social · Jul 23

Changes in #BoneMineralDensity were mediated by changes in E2 and testosterone among women and men, respectively, with #T2D undergoing weight loss.

@erinmichos.bsky.social @johnshopkinssph.bsky.social @jhu.edu @imperialcollegeldn.bsky.social @uthsc.bsky.social

Weight Loss-Induced Sex Hormone Changes May Affect BMD Loss in T2D

Weight loss-induced sex hormone changes had a mediating effect on bone mineral density loss among patients with type 2 diabetes.

www.endocrinologyadvisor.com

1 1

Reposted by Erin Michos, MD

Seme Burka @semeburka.bsky.social · Jul 16

For patients who can’t tolerate statins, or need more LDL-C lowering despite high-intensity therapy, bempedoic acid is a proven option that’s often overlooked.
@erinmichos.bsky.social @ciccaronecenter.bsky.social
Quick read our case 🔗 @accintouch.bsky.social

learn.acc.org/Page/Bempedo...

5 6

Reposted by Erin Michos, MD

American Journal of Preventive Cardiology @ajpcardio.bsky.social · Jul 17

📢 New in AJPC: Study explores how gender and menopause status impact BP reduction in a mobile health self-management program for hypertension. @drmarthagulati.bsky.social @erinmichos.bsky.social

📱💡 Personalized care matters.

ow.ly/H8ob50WrnQk

#Hypertension #Cardiology #mHealth #AJPC

1 5 4

Reposted by Erin Michos, MD

American Society for Preventive Cardiology @aspcardio.bsky.social · Jun 19

We’re proud to celebrate @ajpcardio.bsky.social — official journal of the ASPC — on its 2024 impact factor of 5.9 & ranking 34 of 230 journals in Cardiac & Cardiovascular Systems! Kudos Dr. Nathan Wong, @erinmichos.bsky.social, & the AJPC community for advancing the field of preventive cardiology.

American Journal of Preventive Cardiology @ajpcardio.bsky.social · Jun 19

AJPC has earned a new impact factor of 5.9 & is now ranked 34 out of 230 journals in Cardiac & Cardiovascular Systems!
Official journal @aspcardio.bsky.social, AJPC is on the rise — thanks to Dr. Nathan Wong, @erinmichos.bsky.social, & our incredible community.
www.sciencedirect.com/journal/amer...

3 5

Reposted by Erin Michos, MD

Patricia George MD @patriciageorge5280.bsky.social · Jun 12

Having a great time and learning a ton at the @nationaljewish.org CV Symposium: Improving Cardiovascular Outcomes: The Next Era of Prevention. AND I got to see Dr. @erinmichos.bsky.social and ask her all my pressing cardiology questions. 🫀❤️👊

2 3

Reposted by Erin Michos, MD

Henry Han @hancardiomd.bsky.social · Jun 12

The impact of federal actions on academic medicine and the U.S. health care system

www.aamc.org/about-us/aam...

@cardioobdoc.bsky.social @arghavansallesmd.medsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social

4 3

Reposted by Erin Michos, MD

Fipco @fipco.bsky.social · Jun 11

Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky

www.lipidjournal.com/article/S193...

2 1

Reposted by Erin Michos, MD

American Journal of Preventive Cardiology @ajpcardio.bsky.social · Jun 10

June 2025 #AJPC Editors’ Message @erinmichos.bsky.social & Dr. Nathan Wong! Dive into cutting-edge articles on AI, psychosocial stress, obesity, chylomicronemia, and more in #CVDPrevention. Plus, a preview of #ASPC2025!

www.sciencedirect.com/science/arti...
#CardioSky @aspcardio.bsky.social

4 2

Reposted by Erin Michos, MD

HCPLive @hcplivenews.bsky.social · Jun 7

New at #HiD25: @erinmichos.bsky.social, director of women's cardiovascular health at Johns Hopkins University, met with us to discuss her presentation on postmenopausal hormone imbalance, obesity, and cardiovascular disease risk in women.

Watch the interview here: www.hcplive.com/view/post-me...

1 2

Reposted by Erin Michos, MD

Johns Hopkins Cardiology @hopkinsheart.bsky.social · Apr 1

A huge congratulations to our Cardiology Fellowship APD, Dr. Anum Minhas, who was awarded the Young Author Achievement Award for @jaccjournals.bsky.social JACC Advances 💖

allisonghaysmd.bsky.social @allisonghaysmd.bsky.social · Apr 1

Congratulations to @anumminhas @theresaboyer
for wining JACC authorship awards for work in Maternal CV Health 👏🏼👏🏼👏🏼
@erinmichos.bsky.social
@hopkinsheart.bsky.social
@accintouch.bsky.social @janetcatov #acc2025

4 7

Reposted by Erin Michos, MD

Vindico Medical Education @vindicomeded.bsky.social · May 22

🍳 FREE CME + breakfast + the latest breakthroughs in #ASCVD treatment

Fri, May 30 | 7:15–8:45 AM at JW Marriott Miami Turnberry Resort and Spa #NLASessions

🔗 vindicoce.com/NLA

@nationallipid.bsky.social @erinmichos.bsky.social @foundationofnla.bsky.social @lipidjournal.bsky.social

CE Breakfast Symposium during #NLASessions
Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk
Friday, May 30 at 7:15 AM

1 3

Reposted by Erin Michos, MD

Vindico Medical Education @vindicomeded.bsky.social · May 19

Don’t miss the CETP comeback story—plus RAPID-FIRE ROUNDTABLE—at our CE breakfast on May 30 during #NLASessions Register here >> vindicoce.com/NLA
@erinmichos.bsky.social
@nationallipid.bsky.social
@lipidjournal.bsky.social
@foundationofnla.bsky.social

2 3

Erin Michos, MD @erinmichos.bsky.social · May 18

Pleased to be a co-author of this study and part of TANDEM steering committee. Given the critical importance of reducing LDL Cholesterol for preventing atherosclerotic cardiovascular disease, more options to lower LDL-C is a good thing!

The Lancet @thelancet.com · May 16

Atherosclerotic cardiovascular disease (ASCVD) contributes substantially to the burden of cardiovascular disease.

A new trial suggests promise for broadening the therapeutic landscape for patients with pre-existing or high risk for ASCVD.

Find out more in our latest issue: tinyurl.com/4vjusubm

Cover of The Lancet May 17, 2025 issue. Quote on cover reads: "the demonstrated efficacy of the obicetrapib–ezetimibe FDC in the TANDEM trial holds promise for broadening the therapeutic landscape for patients with pre-existing or high risk for atherosclerotic cardiovascular disease."

6

Reposted by Erin Michos, MD

Parham Eshtehardi MD @cardioobdoc.bsky.social · May 14

Long-term trials of #colchicine for secondary prevention of vascular events: a meta-analysis

#CardioSky
academic.oup.com/eurheartj/ad...
@escardio.bsky.social @anastasiasmihaili.bsky.social @victoriadelgadomd.bsky.social @gimelliale.bsky.social @load-dependent.bsky.social @dmljmd.bsky.social

1 5 6

Erin Michos, MD @erinmichos.bsky.social · May 13

Join me in Nashville Sept 5-7 for the American Society of Echocardiography @ase360.bsky.social Scientific Sessions and 50th year Anniversary! Join us for late breaking innovations & updates in cardiovascular ultrasound. #echofirst #ASE2025 #EchoSky

1 4 9

Reposted by Erin Michos, MD

Sharonne N. Hayes MD @sharonnehayes.bsky.social · May 9

Just finished up a great 2 days of learning & developing solutions for better heart health for women at Hello Heart’s 2nd annual conference. Rock star faculty & engaged participants.
@erinmichos.bsky.social @jaynemorgan.bsky.social @womenheart.bsky.social

2 4 5

Erin Michos, MD @erinmichos.bsky.social · May 8

Exciting news for #liver health! The #GLP1RA #semaglutide significantly improved #MASH & fibrosis.

NEJM.org @nejm.org · Apr 30

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky

The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.

1 8

Erin Michos, MD @erinmichos.bsky.social · May 8

@eassociety.bsky.social #EASCongress2025 #lipids #obicetrapib

3 4

Reposted by Erin Michos, MD

NEJM.org @nejm.org · May 7

In a randomized trial of patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full BROADWAY trial results: nej.md/4lKsmMK

@eassociety.bsky.social | #EASCongress2025

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk | NEJM

Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fu...

nej.md

1 7 20

Erin Michos, MD @erinmichos.bsky.social · May 8

Pleased to share our results from the TANDEM Trial published in @thelancet.bsky.social today and presented at EAS: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction: a phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan...

2 6 12

Reposted by Erin Michos, MD

Vindico Medical Education @vindicomeded.bsky.social · May 7

Excited to be a part of #NLASessions! We're bringing an exciting #CE breakfast symposium on CETP inhibitors on Fri 5/30. Register here: vindicoce.com/NLA

#ASCVD #lipid #lipidology #cardiovasculardisease #dyslipidemia #MedSky @nationallipid @Lipidjournal @Foundationofnla @erinmichos.bsky.social

1 1